Four-year outcomes from a prospective phase II clinical trial of moderately hypofractionated proton therapy for localized prostate cancer.

Amardeep S Grewal,Caitlin Schonewolf,Eun Jeong Min,Hann-Hsiang Chao,Stefan Both,Sarah Lam,Susan Mazzoni,Justin Bekelman,John Christodouleas,Neha Vapiwala

International Journal of Radiation Oncology*Biology*Physics（2019）

引用 32|浏览13

暂无评分

摘要

HFPT is associated with low rates of toxicity and does not appear to negatively impact 4-year patient reported urinary and bowel health. Further comparative analyses are warranted to better understand differences between proton and photon HFRT.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要